Envisions Using Bullfrog AI Innovative Artificial Intelligence Technology to Expand KBP’s Diverse Product Pipeline
KBP BioSciences USA, a clinical stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, has entered into a Memorandum of Understanding (MOU) with BullFrog AI Inc.
KBP Bioscience presently has three clinical stage compounds having obtained US FDA and Chinese CFDA IND approvals and its lead program, KBP-5074, is progressing through a global Phase 2b clinical trial for uncontrolled hypertension in moderate and severe Chronic Kidney Disease patients.
Read More: Quadruple Success for UiPath as It Scoops Four Prestigious Awards in Four Weeks
KBP Biosciences is also actively seeking to identify additional promising therapeutic opportunities and build out its product portfolio. The MOU envisions the two organizations collaborating in utilizing BullFrog AI’s proprietary bfLEAP artificial intelligence technology based on a graph analytics platform developed at the Johns Hopkins University Applied Physics Laboratory.
“The mission of KBP Biosciences is to identify and develop new medicines for global unmet medical needs. This collaborative arrangement sets the stage for KBP Biosciences to work with BullFrog AI and Johns Hopkins University to enable us to potentially develop valuable and needed therapies faster and more efficiently,” said Zhenhua Huang, The Executive Chairman of KBP Biosciences.
“We are very excited to work with KBP on expanding their portfolio of products. Our mission is to build significant value for our partners by helping identify new drug candidates and allow patients to gain access to treatments, improve response and see a reduction in side effects,” said Vin Singh, Founder and CEO of BullFrog AI.
Read More: ArcBlock Upgrades Forge Application Framework with New Features and Tools for Blockchain Developers
